Navigation Links
Prostate specific antigen screening declines after 2012 USPSTF recommendations
Date:3/13/2014

New York, NY, March 13, 2014 Researchers at Case Western Reserve University and University Hospitals Case Medical Center have assessed the impact of the 2012 U.S. Preventive Services Task Force (USPSTF) recommendations against routine prostate specific antigen (PSA) cancer screenings, which cited evidence that the risks of screening outweigh the benefits. Results of the current study indicate that the USPSTF recommendations have resulted in a decrease in the number of PSA screenings ordered by doctors, with the greatest decline seen among urologists. The findings are published in the June issue of The Journal of Urology.

PSA screening has not been without controversy. While early detection is the key to treating prostate cancer, routine PSA screenings have come under scrutiny because of potential over diagnosis and overtreatment of "clinically insignificant" prostate cancer.

In the current study, investigators looked at data for PSA tests performed at University Hospitals Case Medical Center and its affiliated facilities from January 2008 to December 2012. During that period, 43,498 PSA screenings were performed, with the majority of the tests ordered by internal medicine (64.9%), followed by family medicine (23.7%), urology (6.1%), and hematology/oncology (1.3%). Screening numbers started to decline in 2009 with the release of the initial PSA screening trial results, and then continued to decline after the USPSTF recommendations were issued.

To explore the specifics of the decline, investigators evaluated data reported for type of medical provider ordering the tests, as well as geographic location of the facility. "The recently published prostate screening trials and the USPSTF recommendations appear to have negatively impacted PSA screening," says lead investigator Dr. Robert Abouassaly, MD, MSc, Assistant Professor of Urology at Case Western Reserve University School of Medicine and University Hospitals Case Medical Center. "These effects were more immediate and pronounced in the urban/academic setting, and more gradual in suburban and rural settings. Decreased prostate cancer screening was observed across all specialties over time, with, interestingly, the greatest impact seen among urologists."

The researchers explain that because for urologists, prostate cancer is a focal point of their day-to-day practice, the changes in PSA screening behavior may have been more rapidly acknowledged. Primary care physician offices manage a broad range of medical topics with varied screening policies and thus there may be a delay in the implementation of new policies. Also, PSA screening policy may not quickly circulate through rural and suburban areas compared to urban/academic practices.

While there is a perceived benefit by some doctors and patients for routine PSA screening, for most men who have an average risk of prostate cancer, an early diagnosis and subsequent aggressive treatment may lead to decreased quality of life. Currently the medical community remains divided on the merits of PSA testing for everyone. "Clinical practice guidelines for prostate cancer screening vary and are controversial due to uncertainty as to whether the benefits of screening ultimately outweigh the risks of over diagnosis and overtreatment," concludes Dr. Abouassaly. "Further study will be needed to determine the long-term effects of these recommendations on screening, diagnosis, treatment, and prognosis of this prevalent malignancy."


'/>"/>

Contact: Linda Gruner
jumedia@elsevier.com
212-633-3923
Elsevier Health Sciences
Source:Eurekalert

Related medicine news :

1. PSA-testing and early treatment decreases risk of prostate cancer death
2. New approach to prostate cancer screening needed
3. UCLA study finds robotic-assisted prostate surgery offers better cancer control
4. More intensive radiotherapy is better than less for localized prostate cancer
5. Prostate cancer advance could improve treatment options
6. Mayo Clinic identifies a key cellular pathway in prostate cancer
7. 3D mapping biopsy finds 3x prostate cancer of ultrasound-guided biopsy
8. Prostate cancer signal reawakens sleeper agent cells in bones
9. Scientists develop powerful new animal model for metastatic prostate cancer
10. Researchers identify possible explanation for link between exercise & improved prostate cancer outcomes
11. Melatonin may lower prostate cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... March 30, 2017 , ... This morning, more ... Trump expressing their support for an independent Vaccine Safety Commission. Five of the ... medical journalist, will hold a press conference at 9:00 AM Friday, March ...
(Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, up to 36% ... other types of metastatic brain tumors(3). Though most meningiomas are benign, metastatic brain tumors ... finding more effective treatment options, the San Diego Gamma Knife Center offers ...
(Date:3/29/2017)... ... March 30, 2017 , ... Grass pollen is the main cause of hay fever in ... The season for grass pollen runs from May to July each year; with the worst ... to do? HayMax™ allergen barrier balms ( http://www.haymax.us ) provide an effective defense against grass ...
(Date:3/29/2017)... (PRWEB) , ... March 30, 2017 , ... Sublime Naturals ... "Spice of Life" or "Wonder Spice", it has been used for thousands of years. ... the East," says Heshelow, author of " Turmeric: How to Use it For Your ...
(Date:3/29/2017)... Baton Rouge, Louisiana (PRWEB) , ... March 29, ... ... trademarked HeartBoost in three Hours at a Walgreens store in Mississippi. AngioGenesis Labs, ... campaign at Walgreens Stores in two southeastern states. Ingredients in HeartBoost, an over ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 29, 2017  Bodycad announced today that it ... 510(k) clearance for its Bodycad Unicompartmental Knee System, ... orthopaedic restoration. Bodycad is the first Canadian company ... implant system. Bodycad,s revolutionary Unicompartmental ... of the patient,s unique anatomical features and kinematics. ...
(Date:3/29/2017)... Mar. 29, 2017 Research and Markets has ... 2017-2021" report to their offering. ... The global energy-based aesthetic devices market to ... The report, Global Energy-Based Aesthetic Devices Market 2017-2021, has ... industry experts. The report covers the market landscape and its growth ...
(Date:3/29/2017)... -- Global intravenous (IV) iron and oral iron market is ... a CAGR of 5%. Iron drugs are ... anemia or other iron deficiencies. Oral iron supplements are recommended ... some cases, oral administrations are not capable of maintaining the ... comes into the picture. Global Intravenous (IV) Iron ...
Breaking Medicine Technology: